U.S. Markets open in 2 hrs 53 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,487.00+7.00 (+0.47%)
As of 11:22AM BST. Market open.
Full screen
Previous Close1,480.00
Open1,482.00
Bid1,487.00 x 175400
Ask1,487.50 x 417900
Day's Range1,472.50 - 1,489.00
52 Week Range1,444.00 - 1,745.56
Volume1,840,821
Avg. Volume7,254,755
Market Cap72.2B
Beta1.15
PE Ratio (TTM)38.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.01 (5.14%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Reuters20 hours ago

    UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

    The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an advisory panel's recommendation in August that the FDA reject the drug. "We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab," He added that the company is seeking to "gain a full understanding of FDA requirements for U.S. approval" and plans to have a follow-up discussion with the agency.

  • Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
    Zacks4 days ago

    Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

    Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

  • Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
    Zacks5 days ago

    Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

    GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.